The drugmaker added $1 billion to its savings target and raised its 2026 revenue outlook, even as COVID sales collapse and several cancer drugs slip.
University of Pennsylvania researchers found a gum made from lablab beans sharply reduced HPV in oral samples — an early, lab-only step toward preventing HPV-linked cancers.
A USC deep-learning model, trained on nearly 15,000 scans, shows which parts of the brain age fastest — and flags accelerated aging in areas hit early by Alzheimer’s.
Vertex raised guidance on $3.2B in quarterly CF sales, yet analysts are watching tiny Sionna Therapeutics, whose experimental drug could layer on top of Vertex’s Trikafta.
The KRAS G12C inhibitor earned the designation for previously treated advanced pancreatic cancer, one of oncology’s hardest targets, based on early-phase trial data.
Researchers explain how the brain “remembers” a higher body weight and defends it, helping explain why weight often returns after diets — or after stopping drugs like Wegovy.
The all-stock merger of equals unites Supernus’s brain-disorder portfolio with Indivior’s addiction treatments, forming a company with 11 marketed drugs.
Vanderbilt researchers created the first compounds to selectively switch a protein family called TAOK on or off — research tools, not drugs, that could open new Alzheimer’s leads.
A Financial Times report of merger talks sent AstraZeneca stock lower as analysts questioned why the fast-growing company would take on such a deal. Neither firm has confirmed.
In three women with stubborn, antibiotic-resistant infections, pairing viruses that kill bacteria with a microbiome transplant reduced recurrences and antibiotic use — but the study is tiny.
Shares jumped 56% on debut as the biotech advances oxnimbi, a once-nightly pill targeting an underlying cause of obstructive sleep apnea, toward a 2027 FDA decision.
Hebrew University researchers show that the overactive gene switches driving tumor growth physically strain and snap DNA — a stress point that might be turned against cancer.